ARCH Venture Fund XII, L.P. → Prime Medicine, Inc. PRME

Stake: 10.40% Shares: 18,587,036 CUSIP: 74168J101 Class: Common Stock, $0.00001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

4 transactions

4 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-08-31

DTC 13.13

36,761,940 shares short · +5.0% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $1.91M

Point72 Asset Mgmt

Post-Filing Returns · since 2025-08-07 on PRME

+1 day

0.0%

+5 days

0.0%

+30 days

0.0%

+60 days

0.0%

+90 days

0.0%

+180 days

0.0%

Anchor price 3.99 on closest trading day on/after 2025-08-07. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-16	Makhni Svetlana Ni	officer	Award	800,000	$3.67	$2.94M
2026-02-26	Reine Allan	director, officer	Award	1,300,000	$4.38	$5.69M
2026-02-23	LEE ANN L.	officer	Award	375,000	$3.34	$1.25M
2026-02-23	Alenson Carman	officer	Award	140,000	$3.34	$468K

Other Filings by ARCH Venture Fund XII, L.P.

Filed	Form	Issuer	Stake	Shares
2026-04-01	SCHEDULE 13D/A	Neumora Therapeutics, Inc. NMRA	18.70%	33,847,838	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →